Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

About Aerie Pharmaceuticals

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AERI
  • CUSIP:
Key Metrics:
  • Previous Close: $39.36
  • 50 Day Moving Average: $22.70
  • 200 Day Moving Average: $17.60
  • 52-Week Range: $10.82 - $39.53
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.85
  • P/E Growth: 0.00
  • Market Cap: $1.10B
  • Outstanding Shares: 27,892,000
  • Beta: 1.22
Profitability:
  • Return on Equity: -1,000.43%
  • Return on Assets: -56.77%
Debt:
  • Debt-to-Equity Ratio: -7.09%
  • Current Ratio: 7.65%
  • Quick Ratio: 7.65%
Additional Links:
Companies Related to Aerie Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $52.67 (33.81% upside)

Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2016HC WainwrightInitiated CoverageBuy$66.00View Rating Details
9/16/2016RBC Capital MarketsReiterated RatingOutperform$51.00 -> $55.00View Rating Details
9/14/2016Canaccord GenuitySet Price TargetBuy$44.00 -> $50.00View Rating Details
9/15/2016Brean CapitalSet Price TargetBuy$48.00View Rating Details
9/15/2016Stifel NicolausBoost Price TargetBuy$40.00 -> $50.00View Rating Details
9/15/2016Needham & Company LLCReiterated RatingBuy$45.00 -> $52.00View Rating Details
9/15/2016Cantor FitzgeraldBoost Price TargetBuy$44.00 -> $50.00View Rating Details
9/15/2016Royal Bank Of CanadaBoost Price TargetOutperform$51.00 -> $55.00View Rating Details
9/13/2016Raymond James Financial Inc.Initiated CoverageOutperform$48.00View Rating Details
9/17/2015JMP SecuritiesBoost Price TargetOutperform$39.00 -> $49.00View Rating Details
6/5/2015Piper Jaffray Cos.Reiterated RatingBuy$7.00 -> $9.00View Rating Details
3/24/2015MLV & Co.Reiterated RatingBuy$40.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.56)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.59)ViewN/AView Earnings Details
5/7/2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.46)($0.58)ViewN/AView Earnings Details
11/11/2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014($0.34)($0.49)ViewN/AView Earnings Details
5/12/2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)
Current Year EPS Consensus Estimate: $-2.80 EPS
Next Year EPS Consensus Estimate: $-2.65 EPS

Dividends

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Ownership Percentage: 8.77%
Institutional Ownership Percentage: 99.66%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aerie Pharmaceuticals (NASDAQ:AERI)
DateHeadline
News IconOverbuying Stock in Focus: Aerie Pharmaceuticals Inc (NASDAQ ... - Post Registrar (NASDAQ:AERI)
postregistrar.com - September 26 at 3:19 PM
News IconAerie Pharmaceuticals Inc. (NASDAQ:AERI) Glaucoma Drug Future Is Looking, Bleak - Scibility Media (NASDAQ:AERI)
scibilitymedia.com - September 23 at 3:47 PM
News IconAnalysts Valuations For Two Stocks: Rowan Companies PLC (NYSE:RDC), Aerie Pharmaceuticals Inc (NASDAQ:AERI) - The Voice Registrar (NASDAQ:AERI)
voiceregistrar.com - September 22 at 3:20 PM
News IconOverbuying Hot Buzz: Aerie Pharmaceuticals Inc (NASDAQ:AERI) - Post Registrar (NASDAQ:AERI)
postregistrar.com - September 22 at 8:49 AM
biz.yahoo.com logoAERIE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex (NASDAQ:AERI)
biz.yahoo.com - September 22 at 8:49 AM
biz.yahoo.com logoAERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:AERI)
biz.yahoo.com - September 22 at 8:49 AM
fool.com logo3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions (NASDAQ:AERI)
www.fool.com - September 21 at 3:52 PM
News IconAerie Pharmaceuticals Continues to Rally (NASDAQ:AERI)
www.financialbuzz.com - September 21 at 10:31 AM
News IconAerie Pharmaceuticals, Inc. (AERI) Broker Price Targets For The Coming Week (NASDAQ:AERI)
magseriesusa.net - September 21 at 10:31 AM
schaeffersresearch.com logoAnalyst Update: Aerie Pharmaceuticals Inc, Bristol-Myers Squibb Co, and Clovis Oncology Inc (NASDAQ:AERI)
www.schaeffersresearch.com - September 21 at 10:31 AM
thestreet.com logoCloudy Outlook for Aerie Pharma's Glaucoma Drug (NASDAQ:AERI)
www.thestreet.com - September 21 at 10:31 AM
schaeffersresearch.com logoAnalyst Update: Aerie Pharmaceuticals Inc, Bristol-Myers Squibb Co, and Clovis Oncology Inc - Schaeffers Research (blog) (NASDAQ:AERI)
www.schaeffersresearch.com - September 20 at 3:21 PM
fool.com logoWhat's Behind Aerie Pharmaceuticals' 12.9% Rally Today (NASDAQ:AERI)
www.fool.com - September 20 at 3:21 PM
News IconActive Momentum Stocks in New Buzz: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), Sanofi (NYSE:SNY) - Street Wise Report (press release) (blog) (NASDAQ:AERI)
streetwisereport.com - September 19 at 4:11 PM
seekingalpha.com logoAerie Pharma: Bullish Thesis Intact - Seeking Alpha (NASDAQ:AERI)
seekingalpha.com - September 19 at 4:11 PM
finance.yahoo.com logoHow to Make Better Trading Decisions (NASDAQ:AERI)
finance.yahoo.com - September 19 at 4:11 PM
News IconAerie Pharma files for secondary offering of $125M - WRAL Tech Wire (NASDAQ:AERI)
wraltechwire.com - September 18 at 3:20 PM
schaeffersresearch.com logoAerie Pharmaceuticals Inc (AERI) Options Traders React to Fresh Highs (NASDAQ:AERI)
www.schaeffersresearch.com - September 18 at 8:06 AM
finance.yahoo.com logo6:32 am Aerie Pharma announces $125 mln in public offerings (NASDAQ:AERI)
finance.yahoo.com - September 17 at 3:20 PM
News IconAerie Pharmaceuticals, Inc. Pipeline Review, Market Growth, Trends and Clinical trial 2016 - 2020 - Medgadget (blog) (NASDAQ:AERI)
www.medgadget.com - September 17 at 8:07 AM
fool.com logoWhy Aerie Pharmaceuticals Shares Are Rallying Another 11.9% Today (NASDAQ:AERI)
www.fool.com - September 17 at 8:07 AM
marketwatch.com logoAerie Pharma announces secondary offering after big stock jump - MarketWatch (NASDAQ:AERI)
www.marketwatch.com - September 16 at 3:21 PM
News IconAerie Pharmaceuticals Inc. (NASDAQ: AERI) Buy Rating Reiterated at Needham & Company LLC - BNB Daily (blog) (NASDAQ:AERI)
www.baseball-news-blog.com - September 16 at 3:21 PM
rttnews.com logoAerie Pharmaceuticals (AERI) Jumped To A New High On Phase 3 Study Results (NASDAQ:AERI)
www.rttnews.com - September 16 at 12:00 PM
marketwatch.com logoAerie Pharmaceuticals Announces Public Offering of Common Stock (NASDAQ:AERI)
www.marketwatch.com - September 16 at 12:00 PM
News IconAerie Pharmaceuticals Raises $125 Million in Public Offerings (NASDAQ:AERI)
ih.advfn.com - September 16 at 12:00 PM
investors.com logoAerie Pharmaceuticals raises US$125mln off the back of phase 3 results share surge (NASDAQ:AERI)
www.proactiveinvestors.com - September 16 at 12:00 PM
marketexclusive.com logoWhy Is Aerie Pharmaceuticals Inc (NASDAQ:AERI) Diluting Its Stock? (NASDAQ:AERI)
marketexclusive.com - September 16 at 12:00 PM
finance.yahoo.com logoCompany News for September 16, 2016 (NASDAQ:AERI)
finance.yahoo.com - September 16 at 12:00 PM
finance.yahoo.com logo40 Trading Lessons from The PlayBook (NASDAQ:AERI)
finance.yahoo.com - September 16 at 12:00 PM
fool.com logoWhy Aerie Pharmaceuticals Is Soaring 54% Today - Motley Fool (NASDAQ:AERI)
www.fool.com - September 15 at 8:31 PM
benzinga.com logoAerie Pharmaceuticals (NASDAQ:AERI), Apogee Enterprises, Inc ... - Benzinga (NASDAQ:AERI)
www.benzinga.com - September 15 at 3:19 PM
smarteranalyst.com logoBull of the Day: Aerie Pharmaceuticals Inc (AERI) - Smarter Analyst (NASDAQ:AERI)
www.smarteranalyst.com - September 15 at 3:19 PM
thestreet.com logoTrending Tickers: AAPL, TMUS, FIT, AERI (NASDAQ:AERI)
realmoney.thestreet.com - September 15 at 3:19 PM
benzinga.com logo4 Stocks Moving In After-Hours: Clinical Trials, Earnings & New Product Lines - Benzinga (NASDAQ:AERI)
www.benzinga.com - September 15 at 12:12 PM
schaeffersresearch.com logoBuzz Stocks: Aerie Pharmaceuticals Inc, JinkoSolar Holding Co., Ltd., and Acacia Research Corp - Schaeffers Research (blog) (NASDAQ:AERI)
www.schaeffersresearch.com - September 15 at 12:12 PM
businesswire.com logoAerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil ... - Business Wire (press release) (NASDAQ:AERI)
www.businesswire.com - September 15 at 12:12 PM
benzinga.com logoAerie Rips 60% After Positive Roclatan Phase 3 Topline Efficacy Results (NASDAQ:AERI)
www.benzinga.com - September 14 at 8:37 PM
streetinsider.com logoAerie Pharma (AERI) Announces Statistically Significant Data from Roclatan Phase 3 Mercury 1 Trial (NASDAQ:AERI)
www.streetinsider.com - September 14 at 8:37 PM
marketwatch.com logoAerie Pharma shares jump more than 60% on eye-drug study results (NASDAQ:AERI)
www.marketwatch.com - September 14 at 8:37 PM
4-traders.com logoAERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:AERI)
www.4-traders.com - September 14 at 8:37 PM
thestreet.com logoAerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results (NASDAQ:AERI)
www.thestreet.com - September 14 at 8:37 PM
News IconAerie's eye drug meets main goal in late-stage study; shares jump (NASDAQ:AERI)
www.channelnewsasia.com - September 14 at 8:37 PM
rttnews.com logoAerie Pharmaceuticals Inc. (AERI) Is Surging On Phase 3 Study Results (NASDAQ:AERI)
www.rttnews.com - September 14 at 8:37 PM
schaeffersresearch.com logoPut Options Pop as Aerie Pharmaceuticals Inc (AERI) Extends Breakout (NASDAQ:AERI)
www.schaeffersresearch.com - September 14 at 8:37 PM
News IconShares Going Lower in Trade: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Post News (NASDAQ:AERI)
www.kentuckypostnews.com - September 14 at 3:20 PM
News IconStock Gapping Higher Before the Bell: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) - Post News (NASDAQ:AERI)
www.kentuckypostnews.com - September 14 at 3:20 PM
smarteranalyst.com logoBiotech Daily Digest: Sarepta Therapeutics Inc (SRPT), Aerie Pharmaceuticals Inc (AERI) - Smarter Analyst (NASDAQ:AERI)
www.smarteranalyst.com - September 14 at 3:20 PM
finance.yahoo.com logoCoverage initiated on Aerie Pharma by Raymond James (NASDAQ:AERI)
finance.yahoo.com - September 14 at 3:20 PM
capitalcube.com logoAerie Pharmaceuticals, Inc. :AERI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:AERI)
www.capitalcube.com - September 14 at 9:40 AM

Social

Aerie Pharmaceuticals (NASDAQ:AERI) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff